Literature DB >> 7790088

Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.

J Kuo1, M Douglas, H K Ree, A A Lindberg.   

Abstract

Pneumolysin from Streptococcus pneumoniae was expressed in Escherichia coli as a glutathione S-transferase fusion protein and purified by affinity and hydroxylapatite chromatography. The purified recombinant pneumolysin (rPL), with a molecular mass of 53 kDa, had a specific activity of 3 x 10(5) hemolytic units per mg of protein on rabbit erythrocytes and reacted identically in immunodiffusion with the antisera against native pneumolysin. The rPL was used as a protein carrier to prepare conjugate vaccine with pneumococcal type 18C polysaccharide (PS18C). The PS18C was directly coupled to rPL by reductive animation or was indirectly coupled to rPL via a spacer molecule, adipic acid dihydrazide. The conjugates were nontoxic for mice and guinea pigs at 100 micrograms per dose. The immunogenicity and protective efficacy of both conjugates were tested in mice. A single dose of either of the vaccines elicited a rise in immunoglobulin G antibody production; after two booster injections of the vaccines, statistically significant booster responses (P < 0.001) to both rPL and PS18C were produced. The sera containing the antibodies to rPL were capable of neutralizing the hemolytic activity of rPL to rabbit erythrocytes and the cytotoxicity of rPL to bovine pulmonary endothelial cells. Immunization with the conjugate vaccines conferred statistically significant protection in mice against lethal challenge with type 18C pneumococci.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790088      PMCID: PMC173362          DOI: 10.1128/iai.63.7.2706-2713.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

Review 1.  Polysaccharide-protein conjugates: a new generation of vaccines.

Authors:  J B Robbins; R Schneerson
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization.

Authors:  B A Schwartz; G R Gray
Journal:  Arch Biochem Biophys       Date:  1977-06       Impact factor: 4.013

4.  The direct coupling of oligosaccharides to proteins and derivatized gels.

Authors:  G R Gray
Journal:  Arch Biochem Biophys       Date:  1974-07       Impact factor: 4.013

5.  The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents.

Authors:  J K Inman; H M Dintzis
Journal:  Biochemistry       Date:  1969-10       Impact factor: 3.162

6.  Properties of purified pneumococcal hemolysin.

Authors:  M K Johnson
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

7.  Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.

Authors:  C J Lee; R A Lock; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

8.  Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.

Authors:  H J Jennings; C Lugowski
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

Review 9.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  7 in total

1.  Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin.

Authors:  Lea-Ann S Kirkham; Johanna M C Jefferies; Alison R Kerr; Yu Jing; Stuart C Clarke; Andrew Smith; Tim J Mitchell
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

Authors:  Lea-Ann S Kirkham; Alison R Kerr; Gill R Douce; Gavin K Paterson; Deborah A Dilts; Dai-Fang Liu; Tim J Mitchell
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.

Authors:  J E Adamou; J H Heinrichs; A L Erwin; W Walsh; T Gayle; M Dormitzer; R Dagan; Y A Brewah; P Barren; R Lathigra; S Langermann; S Koenig; S Johnson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

Authors:  Jun-Young Seo; Seung Yong Seong; Byung-Yoon Ahn; Ick Chan Kwon; Hesson Chung; Seo Young Jeong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.

Authors:  A D Ogunniyi; R L Folland; D E Briles; S K Hollingshead; J C Paton
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Mouse, but not human, ApoB-100 lipoprotein cholesterol is a potent innate inhibitor of Streptococcus pneumoniae pneumolysin.

Authors:  Kristin R Wade; Eileen M Hotze; David E Briles; Rodney K Tweten
Journal:  PLoS Pathog       Date:  2014-09-04       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.